Zhu J, Leng X, Yin J
Department of Surgery, Beijing Medical University.
Zhonghua Wai Ke Za Zhi. 1997 Feb;35(2):92-4.
Changes of hepatic venous wedge pressure (WHVP) and portal venous pressure (PVP) in fourteen patients with postnecrotic cirrhosis proved pathologically and seven patients with colon carcinoma without hepatopathy were observed before and after the infusion of alpha-adrenergic receptor antagonist phentolamine from peripheral venous. The results indicate that phentolamine can reduce WHVP and PVP of cirrhotic patients with portal hypertension efficiently (0.56-0.63 kPa, 0.42-0.50 kPa, respectively, P < 0.01), but it effects arterial diastolic pressure and heart rate simultaneously (arterial diastolic pressure reduced by 0.94-10.7 kPa, while heart rate increased by 8.67-10.67 per minute). Phentolamine doec not reduce portal pressure on patients without portal hypertension.
对经病理证实的14例坏死后肝硬化患者和7例无肝病的结肠癌患者,在经外周静脉输注α-肾上腺素能受体拮抗剂酚妥拉明前后,观察肝静脉楔压(WHVP)和门静脉压力(PVP)的变化。结果表明,酚妥拉明可有效降低门静脉高压肝硬化患者的WHVP和PVP(分别降低0.56 - 0.63kPa和0.42 - 0.50kPa,P < 0.01),但同时会影响动脉舒张压和心率(动脉舒张压降低0.94 - 10.7kPa,心率每分钟增加8.67 - 10.67次)。酚妥拉明对无门静脉高压的患者不降低门静脉压力。